Cargando…
Unveiling CD59-Antibody Interactions to Design Paratope-Mimicking Peptides for Complement Modulation
CD59 is an abundant immuno-regulatory human protein that protects cells from damage by inhibiting the complement system. CD59 inhibits the assembly of the Membrane Attack Complex (MAC), the bactericidal pore-forming toxin of the innate immune system. In addition, several pathogenic viruses, includin...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218266/ https://www.ncbi.nlm.nih.gov/pubmed/37239905 http://dx.doi.org/10.3390/ijms24108561 |
_version_ | 1785048733237379072 |
---|---|
author | Sandomenico, Annamaria Ruggiero, Alessia Iaccarino, Emanuela Oliver, Angela Squeglia, Flavia Moreira, Miguel Esposito, Luciana Ruvo, Menotti Berisio, Rita |
author_facet | Sandomenico, Annamaria Ruggiero, Alessia Iaccarino, Emanuela Oliver, Angela Squeglia, Flavia Moreira, Miguel Esposito, Luciana Ruvo, Menotti Berisio, Rita |
author_sort | Sandomenico, Annamaria |
collection | PubMed |
description | CD59 is an abundant immuno-regulatory human protein that protects cells from damage by inhibiting the complement system. CD59 inhibits the assembly of the Membrane Attack Complex (MAC), the bactericidal pore-forming toxin of the innate immune system. In addition, several pathogenic viruses, including HIV-1, escape complement-mediated virolysis by incorporating this complement inhibitor in their own viral envelope. This makes human pathogenic viruses, such as HIV-1, not neutralised by the complement in human fluids. CD59 is also overexpressed in several cancer cells to resist the complement attack. Consistent with its importance as a therapeutical target, CD59-targeting antibodies have been proven to be successful in hindering HIV-1 growth and counteracting the effect of complement inhibition by specific cancer cells. In this work, we make use of bioinformatics and computational tools to identify CD59 interactions with blocking antibodies and to describe molecular details of the paratope–epitope interface. Based on this information, we design and produce paratope-mimicking bicyclic peptides able to target CD59. Our results set the basis for the development of antibody-mimicking small molecules targeting CD59 with potential therapeutic interest as complement activators. |
format | Online Article Text |
id | pubmed-10218266 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102182662023-05-27 Unveiling CD59-Antibody Interactions to Design Paratope-Mimicking Peptides for Complement Modulation Sandomenico, Annamaria Ruggiero, Alessia Iaccarino, Emanuela Oliver, Angela Squeglia, Flavia Moreira, Miguel Esposito, Luciana Ruvo, Menotti Berisio, Rita Int J Mol Sci Article CD59 is an abundant immuno-regulatory human protein that protects cells from damage by inhibiting the complement system. CD59 inhibits the assembly of the Membrane Attack Complex (MAC), the bactericidal pore-forming toxin of the innate immune system. In addition, several pathogenic viruses, including HIV-1, escape complement-mediated virolysis by incorporating this complement inhibitor in their own viral envelope. This makes human pathogenic viruses, such as HIV-1, not neutralised by the complement in human fluids. CD59 is also overexpressed in several cancer cells to resist the complement attack. Consistent with its importance as a therapeutical target, CD59-targeting antibodies have been proven to be successful in hindering HIV-1 growth and counteracting the effect of complement inhibition by specific cancer cells. In this work, we make use of bioinformatics and computational tools to identify CD59 interactions with blocking antibodies and to describe molecular details of the paratope–epitope interface. Based on this information, we design and produce paratope-mimicking bicyclic peptides able to target CD59. Our results set the basis for the development of antibody-mimicking small molecules targeting CD59 with potential therapeutic interest as complement activators. MDPI 2023-05-10 /pmc/articles/PMC10218266/ /pubmed/37239905 http://dx.doi.org/10.3390/ijms24108561 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sandomenico, Annamaria Ruggiero, Alessia Iaccarino, Emanuela Oliver, Angela Squeglia, Flavia Moreira, Miguel Esposito, Luciana Ruvo, Menotti Berisio, Rita Unveiling CD59-Antibody Interactions to Design Paratope-Mimicking Peptides for Complement Modulation |
title | Unveiling CD59-Antibody Interactions to Design Paratope-Mimicking Peptides for Complement Modulation |
title_full | Unveiling CD59-Antibody Interactions to Design Paratope-Mimicking Peptides for Complement Modulation |
title_fullStr | Unveiling CD59-Antibody Interactions to Design Paratope-Mimicking Peptides for Complement Modulation |
title_full_unstemmed | Unveiling CD59-Antibody Interactions to Design Paratope-Mimicking Peptides for Complement Modulation |
title_short | Unveiling CD59-Antibody Interactions to Design Paratope-Mimicking Peptides for Complement Modulation |
title_sort | unveiling cd59-antibody interactions to design paratope-mimicking peptides for complement modulation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218266/ https://www.ncbi.nlm.nih.gov/pubmed/37239905 http://dx.doi.org/10.3390/ijms24108561 |
work_keys_str_mv | AT sandomenicoannamaria unveilingcd59antibodyinteractionstodesignparatopemimickingpeptidesforcomplementmodulation AT ruggieroalessia unveilingcd59antibodyinteractionstodesignparatopemimickingpeptidesforcomplementmodulation AT iaccarinoemanuela unveilingcd59antibodyinteractionstodesignparatopemimickingpeptidesforcomplementmodulation AT oliverangela unveilingcd59antibodyinteractionstodesignparatopemimickingpeptidesforcomplementmodulation AT squegliaflavia unveilingcd59antibodyinteractionstodesignparatopemimickingpeptidesforcomplementmodulation AT moreiramiguel unveilingcd59antibodyinteractionstodesignparatopemimickingpeptidesforcomplementmodulation AT espositoluciana unveilingcd59antibodyinteractionstodesignparatopemimickingpeptidesforcomplementmodulation AT ruvomenotti unveilingcd59antibodyinteractionstodesignparatopemimickingpeptidesforcomplementmodulation AT berisiorita unveilingcd59antibodyinteractionstodesignparatopemimickingpeptidesforcomplementmodulation |